Entera Bio's book value per share for the quarter that ended in Sep. 2024 was $0.18.
During the past 12 months, Entera Bio's average Book Value Per Share Growth Rate was -18.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -6.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -16.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Entera Bio was -3.90% per year. The lowest was -15.10% per year. And the median was -6.40% per year.
Entera Bio's current price is $2.16. Its book value per share for the quarter that ended in Sep. 2024 was $0.18. Hence, today's PB Ratio of Entera Bio is 12.20.
During the past 9 years, the highest P/B Ratio of Entera Bio was 19.33. The lowest was 1.01. And the median was 3.90.
Warning Sign:
Entera Bio Ltd stock PB Ratio (=12.43) is close to 3-year high of 12.43
Entera Bio Book Value per Share Historical Data
The historical data trend for Entera Bio's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Entera Bio's Book Value per Share
For the Biotechnology subindustry, Entera Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Entera Bio's PB Ratio falls into.
Entera Bio Book Value per Share Calculation
Entera Bio's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Entera Bio (NAS:ENTX) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Entera Bio Book Value per Share Related Terms
Thank you for viewing the detailed overview of Entera Bio's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENTX has been successfully added to your 